Lipocine (NASDAQ:LPCN) Announces Quarterly Earnings Results

Lipocine (NASDAQ:LPCN) announced its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08, FiscalAI reports. The company had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.21 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%.

Lipocine Price Performance

Shares of NASDAQ:LPCN traded up $0.04 during trading on Tuesday, hitting $2.15. 20,366 shares of the company’s stock were exchanged, compared to its average volume of 228,502. The business’s 50-day simple moving average is $2.28 and its 200 day simple moving average is $4.87. Lipocine has a 52-week low of $1.81 and a 52-week high of $12.37. The company has a market cap of $17.68 million, a price-to-earnings ratio of -1.14 and a beta of 0.44.

Hedge Funds Weigh In On Lipocine

Several hedge funds have recently modified their holdings of LPCN. Squadron Capital Management LLC bought a new stake in Lipocine in the 4th quarter valued at $4,256,000. Diadema Partners LP bought a new stake in shares of Lipocine in the fourth quarter worth about $2,095,000. Ikarian Capital LLC bought a new stake in shares of Lipocine in the fourth quarter worth about $1,602,000. Geode Capital Management LLC lifted its position in shares of Lipocine by 2.2% in the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock worth $502,000 after buying an additional 1,374 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in Lipocine during the fourth quarter valued at approximately $441,000. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Wall Street Analysts Forecast Growth

LPCN has been the topic of a number of recent research reports. Weiss Ratings cut Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. HC Wainwright reaffirmed a “neutral” rating on shares of Lipocine in a research note on Monday, April 6th. Finally, Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $15.00.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.